Castle Biosciences, Inc. - SIC # 8071 - MEDICAL LABORATORIES

Ticker Exchange SIC # Website Latest Ticker
CSTL Nasdaq 8071 castlebiosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Castle Biosciences, Inc.

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management - Sep 30th, 2026 2:30 pm
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus - Sep 28th, 2026 5:00 am
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™ - Sep 24th, 2026 2:30 pm
Castle Biosciences to Open New Laboratory Facility in Scottsdale - Sep 22nd, 2026 5:00 am
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus - Sep 15th, 2026 5:00 am
JAAD Publication Shows Improved Performance of DecisionDx®-SCC - Sep 9th, 2026 2:30 pm
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know - Aug 28th, 2026 10:00 am
Castle Biosciences (CSTL) Rallies On Earnings Optimism, Is The Stock Still Cheap? - Aug 26th, 2026 7:10 pm
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect? - Aug 25th, 2026 7:55 am
Castle Biosciences to Participate in Upcoming Investor Conferences - Aug 20th, 2026 5:00 am
Castle Biosciences Approved for Dual Listing on Nasdaq Texas - Aug 17th, 2026 5:00 am
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction - Aug 12th, 2026 11:01 pm
Castle Biosciences, Inc. Q2 2026 Earnings Call Summary - Jul 31st, 2026 6:30 am
Castle Biosciences Inc (CSTL) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% to $103. ... - Jul 30th, 2026 11:03 pm
Castle Biosciences Q2 Earnings Call Highlights - Jul 30th, 2026 4:04 pm
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates - Jul 30th, 2026 4:00 pm
Castle Biosciences Reports Second Quarter 2026 Results - Jul 30th, 2026 2:05 pm
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference - Jul 22nd, 2026 5:00 am
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test - Jul 14th, 2026 2:30 pm